Is xgeva used for bone metastases in lung cancer?

How does Xgeva fit into lung cancer treatment?

Xgeva is approved for skeletal-related events prevention in adults with bone metastases from solid tumors. This approval covers lung cancer patients who have developed bone involvement.

Why do patients with lung cancer seek Xgeva?

Bone metastases occur in 30-40% of lung cancer cases. Patients ask about Xgeva mainly to reduce fracture risk, spinal cord compression, and the need for radiation or surgery to bone sites.

What is the clinical evidence supporting its use?

Studies show Xgeva delays time to first skeletal-related event by 4-5 months compared to zoledronic acid in patients with lung cancer and bone metastases. Patients keep receiving Xgeva indefinitely as long as performance status allows.

How does Xgeva differ from Zometa?

Xgeva (denosumab) is a monoclonal antibody that binds RANKL directly. Zometa (zoledronic acid) is a bisphosphonate that works through mevalonate pathway inhibition. Xgeva requires subcutaneous injection rather than infusion.

When does Xgeva patent expire?

The primary U.S. patent covering Xgeva expires in 2024. Biosimilars may enter market after patent expiry.